Zydus Lifesciences receives tentative USFDA approval for Azilsartan Medoxomil and Chlorthalidone tablets for high blood pressure treatment.
Zydus Lifesciences receives tentative USFDA approval for Azilsartan Medoxomil and Chlorthalidone tablets, indicated for high blood pressure treatment. These combination products, with annual sales of $77.9mn in the US, will be manufactured at the company's Ahmedabad facility. Zydus now has 397 approvals and has filed over 460 ANDAs since the commencement of the filing process in FY 200.
June 14, 2024
3 Articles